title: Fungal infections in pediatric intensive care units.
abstract: Pediatric fungal infections are associated with significant morbidity and mortality. Few adequately powered antifungal trials have been performed in neonates and children. Neonatologists and pediatricians are reliant on adult trials when managing candidemia. Recent guidelines from the Infectious Diseases Society of America recommend fluconazole or an echinocandin for empiric therapy in suitable candidates, with a preference for an echinocandin in patients with moderate-to severe disease, recent azole exposure, or high risk of C. glabrata or C. krusei infection.
authors.affiliation: Department of Medicine M. Aresu, University of Cagliari, Cagliari, Italy.
authors.forename: Gabriele
authors.initials: G
authors.lastname: Finco
authors.forename: Daniela
authors.initials: D
authors.lastname: Sanna
authors.forename: Maurizio
authors.initials: M
authors.lastname: Evangelista
authors.forename: Paolo
authors.initials: P
authors.lastname: Mura
authors.forename: Mario
authors.initials: M
authors.lastname: Musu
mesh_terms: D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use; D018890:Chemoprevention / Q000379:methods; D002648:Child; D054714:Echinocandins / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D015278:Intensive Care Units, Pediatric / Q000706:statistics & numerical data*; D009181:Mycoses / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control*; D012307:Risk Factors
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins